Invest1 publisher3 min readPublished
Aeon needs nearly 10,000 individual consents before Aware Health's records can move
The Zurich company's seed extension takes its total past $14 million. It buys the core assets of a Berlin startup that raised $15 million on its own in 2022, plus more than 45 blood-draw sites and live lab integrations.
The Investor · Invest desk
What happened
- Zurich-based Aeon has closed a seed extension that takes its total seed funding above $14 million, and acquired the core assets of Germany's Aware Health.
- Aware Health had raised $15 million in its own 2022 seed round in Berlin, where it was building a recurring consumer blood-testing model, before its assets went into Aeon's German expansion.
- Aeon reports that more than 90% of its check-ups surface findings customers can act on and that 15.4% produce a significant finding. Both figures are its own and unaudited.
Compiled by The InvestorSomething wrong?How this is made
Why it matters
- constraint The draw sites and lab integrations transfer on signature. The health histories move only with each customer's consent, and Aeon has to win that consent customer by customer before the longitudinal record it paid for is usable.
- cost Aware's 2022 syndicate put in $15 million and exited through an asset sale. The price was never published, so seed investors in European preventive health have a comparable without a number.
- decision Lucis and Ahead Health, both freshly funded, now choose between opening their own draw sites in Germany and bidding for the next seed-stage platform that stalls.
- contradiction Araya Ventures calls the imaging-plus-blood-plus-AI combination unique in Europe, while the same report describes Ahead Health selling that combination in Germany and the Netherlands.
Aware Health's more than 45 blood-draw locations, its live laboratory integrations and its menu of over 100 biomarkers come across under the deal [7]. The customer records move only where each customer gives explicit consent, in line with GDPR [8]. Nearly 10,000 active customers is nearly 10,000 separate yes answers [7].
The price is undisclosed [21]. What went in was $15 million, in a single 2022 seed round [4]. Against nearly 10,000 active customers that is about $1,500 of investor money per customer [16], and spread across the draw network it comes to roughly 220 customers a site [17].
Aeon's own cumulative seed is reported as above $14 million [1], built on the 8.2 million euro round it raised in June 2025 [3]. The extension is co-led by Araya Ventures, with Concentric, GoHub Ventures, Kadmos Capital, Calm/Storm Ventures, N&V Capital and Bigwave Capital [2]. Aware's one round in 2022 was larger than the floor Aeon has disclosed for everything it has raised [19]. Ferdinand Schmidt-Thome, co-founder of Aware Health, said: "The acquisition gives what we built the opportunity to continue growing as part of a broader preventive-health offering" [11].
Tim Seithe founded Aeon in 2023, after building and selling Tillhub to KKR-owned Unzer [5], and he put the purchase in units of time. "The acquisition of Aware Health accelerates that vision by two years, and this round gives us everything we need to execute," said Seithe [10]. Aeon has been live in Germany since early 2026, already its fastest-growing market [6].
In my view this is an asset sale by a 2022-vintage consumer diagnostics company that did not reach a Series A, and it would take more than one deal to call it a roll-up. The larger cheques in European preventive health are going the other way. Paris-based Lucis raised an $8.5 million seed in December 2025 and a $20 million Series A four months later [14], roughly twice the floor on Aeon's seed [20]. Zurich rival Ahead Health went from a $6 million seed to $10 million seven months later, while expanding into Germany and the Netherlands [13]. If most of Aware's customers consent and Aeon prices a Series A off the combined cohort, then buying the network was cheaper than building it, and I am wrong about which side of this deal got the better terms.
Rupa Popat, founder and managing partner at Araya Ventures, said the combination of imaging, recurring blood diagnostics and AI "creates a longitudinal health picture that no other platform in Europe offers" [12]. The same report has Ahead Health combining blood panels, whole-body MRI and AI in the same two markets [13]. Aeon's clinical yield figures are its own and unaudited: more than 90% of check-ups surface findings customers can act on, with a significant-finding rate of 15.4% [9]. That is about one check-up in six and a half [18]. The company is also hiring, with computational neuroscientist Pablo Tano joining as AI Lead [15].
What to watch
- An independently audited version of Aeon's 90% actionable and 15.4% significant-finding rates.
- Whether Ahead Health or Lucis buys draw-site capacity in Germany instead of opening its own.
- Disclosure of the extension's size in dollars, separate from the 8.2 million euro June 2025 round.